Opthea Announces Completion of Sozinibercept Drug Substance PPQ Campaign
Wednesday, 18 September 2024, 04:31
Significant Milestone in Sozinibercept Development
Opthea has successfully completed the drug substance PPQ campaign for sozinibercept, a critical phase in the manufacturing process. This achievement supports the potential BLA filing for sozinibercept aimed at treating wet AMD (age-related macular degeneration).
Details of the Drug Substance Campaign
- Three consecutive commercial-scale batches have been produced, showcasing the robustness of the manufacturing process.
- Opthea aims to provide a progress update on the drug product PPQ campaign in early stages of next year.
As developments continue, the medical community eagerly awaits further insights into the BLA submission timeline.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.